Why is Twitter so mean to Axovant Sciences? Will sci-fi new medicines ever go mainstream? And what are oncologists even talking about?
We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a discussion of how biotech’s biggest recent blow-up hopes to turn things around, an explanation of biotech jargon that will unnerve actual statisticians, and an interview with Nina Kjellson, a VC at Canaan Partners, about the future of cell and gene therapy. Then comes a lightning round about the diverging fates of various CEOs.
I wouldn’t be surprised to see Headspace’s surprise indication be hypertension.
Comments are closed.